Supriya Lifescience Limited Earnings Review & Business Outlook by Director Saloni Wagh | Saloni Wagh, Director, Supriya Lifescience Limited. 00:10:00
Saloni Wagh, Director of Supriya Lifescience Limited, highlights strong revenue growth of 33%, driven by a 70% increase in volume sales in regulated markets. Margin expansion has been sustained at 28-30%, supported by backward integration and stable pricing. The company's capacity is set to expand to 900k KL by Q1 FY25, projected to drive 50-65% revenue growth. Supriya is focusing on key markets in Europe, Brazil, and the US, with potential growth opportunities in Asia, particularly Japan and China.
